公开(公告)号：EP3130592A1

公开(公告)日：2017-02-15

申请号：EP15777444.9

申请日：2015-03-30

申请人： Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. ,  Humanwell Healthcare (Group) Co., Ltd. ,  Medshine Discovery Inc.

发明人： DING, Zhaozhong ,  CHEN, Shuhui ,  LI, Gang ,  WANG, Cailin ,  ZHANG, Zhibo ,  TU, Ronghua ,  WANG, Cailin ,  YUE, Yang ,  ZHANG, Zhibo ,  CHEN, Hailiang ,  SUN, Wenjie ,  HUANG, Lu

IPC分类号： C07D487/04 ,  C07D519/00 ,  A61P35/00 ,  A61P25/00 ,  A61P9/10 ,  A61P29/00 ,  A61P3/10

CPC分类号： C07D487/04 ,  C07D519/00

摘要： Disclosed is a series of analogues of 4H-pyrazolo[1,5-a]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

摘要翻译： 公开了一系列4H-吡唑并[1,5-a]苯并咪唑化合物的类似物作为PARP抑制剂。 特别地，本发明中公开的是式（I）所示的化合物或其药学上可接受的盐作为PARP抑制剂。

公开(公告)号：EP3978486A1

公开(公告)日：2022-04-06

申请号：EP20814441.0

申请日：2020-05-22

申请人： Medshine Discovery Inc.

发明人： LI, Gang ,  WANG, Kun ,  HU, Lihong ,  DING, Charles Z.

IPC分类号： C07D401/12 ,  A61K31/506 ,  A61K31/513 ,  A61P35/00

摘要： A crystal form and a salt form of a uracil compound acting as a c-MET/AXL inhibitor and a preparation method therefor, specifically relating to the crystal form and the salt form of the compound shown in formula (I), and also comprising an application of the crystal form and the salt form in the preparation of drugs for the treatment of tumours.

公开(公告)号：EP3357925A1

公开(公告)日：2018-08-08

申请号：EP16850379.5

申请日：2016-09-29

申请人： Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. ,  Humanwell Healthcare (Group) Co., Ltd. ,  Medshine Discovery Inc.

发明人： WANG, Xuehai ,  DING, Charles Z. ,  SHEN, Jie ,  CHEN, Shuhui ,  LI, Lie ,  LI, Gang ,  XU, Yong ,  WANG, Cailin ,  TU, Ronghua ,  WANG, Jimeng ,  YUE, Yang ,  DENG, Biao ,  CHEN, Hailiang ,  LIU, Hui ,  SUN, Wenjie ,  WANG, Cong ,  HUANG, Lu ,  WANG, Zheng ,  LI, Weidong

IPC分类号： C07D487/04 ,  C07D401/04 ,  A61P35/00

CPC分类号： C07D487/04 ,  C07B2200/13 ,  C07C57/145 ,  C07D401/04

摘要： Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof.

公开(公告)号：EP3169368A1

公开(公告)日：2017-05-24

申请号：EP15822852.8

申请日：2015-07-13

申请人： Medshine Discovery Inc.

发明人： LI, Chun Sing ,  LI, Jian ,  CANG, Yong ,  CHEN, Shuhui ,  LI, Gang ,  XU, Xiongbin ,  LU, Lun

IPC分类号： A61K47/50 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/3015 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6889 ,  C07K16/2863 ,  C07K2317/24

摘要： The present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.

摘要翻译： 本发明涉及含有酰胺替代物和连接细胞毒性药物与抗体的常规或新型溶酶体酶促可切割二肽单元的接头。 本发明还涉及衍生自这些酰胺替代物接头的ADC（抗体 - 药物缀合物）用于治疗癌症。

公开(公告)号：EP3719012A1

公开(公告)日：2020-10-07

申请号：EP18880588.1

申请日：2018-11-23

申请人： Medshine Discovery Inc.

发明人： LI, Jinping ,  XU, Xiongbin ,  LI, Gang ,  HU, Lihong ,  DING, Charles Z. ,  ZHOU, Yaling ,  HU, Guoping ,  LI, Jian ,  CHEN, Shuhui

IPC分类号： C07D401/12 ,  A61K31/506 ,  A61K31/513 ,  A61P35/00

摘要： Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.

公开(公告)号：EP3473628A1

公开(公告)日：2019-04-24

申请号：EP17812699.1

申请日：2017-06-13

申请人： Medshine Discovery Inc.

发明人： LU, Lun ,  ZHANG, Zhibo ,  LI, Gang ,  HU, Lihong ,  DING, Charles Z. ,  CHEN, Shuhui

IPC分类号： C07D495/14 ,  C07D491/147 ,  C07D487/14 ,  C07D498/14 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61P35/00 ,  A61P3/10 ,  A61P19/02 ,  A61P29/00

摘要： Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.